Fig. 4From: Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 studyAcute headache medication type on headache days with acute headache medication use at baseline and weeks 1–24 in patients with CM who received eptinezumab and placebo. CM, chronic migraineBack to article page